DeCure's autonomous Longevity AI scientist is researching a drug-repurposing hypothesis for age related macular degeneration 4 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAge related macular degeneration 4 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for age related macular degeneration 4 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
complement factor H (CFH) — CFH is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet mlidrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5O32 · 4.20620907647 Å · ligand MALONATE ION (MLI). Experimental structure, not a prediction.
What the evidence adds up to
Albino rats exposed to 3000-lux cyclic light for one month developed retinal degeneration with loss of photoreceptor outer segments and about two-thirds of the outer nuclear layer, plus sub-retinal pigment epithelium neovascularisation. After three months the outer nuclear layer was almost entirely absent and choroidal neovascularisation penetrated Bruch’s membrane into the outer retina. By six months there were multiple foci of choroidal neovascularisation, retinal pigment epithelial fibrous metaplasia, and connective tissue bands containing blood vessels extending into the retina. All light-exposed animals showed increased staining for 4-hydroxy-2-nonenal and nitrotyrosine, markers of oxidative damage. Optical coherence tomography and angiography confirmed retinal thinning and leaky new vessels. The model is intended to allow study of pathogenesis and treatment of age-related macular degeneration.
In cultured human retinal pigment epithelium cells and in mouse retinal pigment epithelium in vivo, transfection with Alu RNA increased expression of the pro-inflammatory cytokines IL-18 and IL-1β and the senescence marker p16INK4a. Treatment with lamivudine (3TC) markedly reduced those increases compared with a negative control. The authors conclude that Alu RNA accumulation contributes to retinal pigment epithelium cell senescence in age-related macular degeneration and that this process can be suppressed by 3TC. The study is limited to cell culture and a mouse model; no human data on lamivudine for age-related macular degeneration are presented.
A 2007 review notes that before photodynamic therapy the only treatment for neovascular age-related macular degeneration was laser photocoagulation, which could stabilise vision but was not enthusiastically received. Photodynamic therapy was the first realistic treatment for subfoveal choroidal neovascularisation. Anti-vascular endothelial growth factor agents then allowed better visual outcomes than mere stabilisation. The review states there is still no cure for the disease.
A 2021 book on macular degeneration covers diagnosis, management, treatment considerations, and vision rehabilitation. It does not report any new clinical trial results or specific drug efficacy data.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Ophthalmology · 2010 · 33 citations
Development of Choroidal Neovascularization in Rats With Advanced Intense Cyclic Light–Induced Retinal Degeneration
AbstractOBJECTIVES: To study the progressive changes of intense cyclic light-induced retinal degeneration and to determine whether it results in choroidal neovascularization (CNV). METHODS: Albino rats were exposed to 12 hours of 3000-lux cyclic light for 1, 3, or 6 months. Fundus examination, fundus photography, fluorescein and indocyanine green angiography, and optical coherence tomography were performed prior to euthanization. Light-exposed animals were euthanized after 1, 3, or 6 months for histopathological evaluation. Retinas were examined for the presence of 4-hydroxy-2-nonenal- and nitrotyrosine-modified proteins by immunofluorescence staining. RESULTS: Long-term intense cyclic light exposure resulted in retinal degeneration with loss of the outer segments of photoreceptors and approximately two-thirds of the outer nuclear layer as well as development of subretinal pigment epithelium neovascularization after 1 month. Almost the entire outer nuclear layer was absent with the presence of CNV, which penetrated the Bruch membrane and extended into the outer retina after 3 months. Absence of the outer nuclear layer, multiple foci of CNV, retinal pigment epithelial fibrous metaplasia, and connective tissue bands containing blood vessels extending into the retina were observed after 6 months. All intense light-exposed animals showed an increased presence of 4-hydroxy-2-nonenal and nitrotyrosine staining. Optical coherence tomographic and angiographic studies confirmed retinal thinning and leakiness of the newly formed blood vessels. CONCLUSIONS: Our results suggest that albino rats develop progressive stages of retinal degeneration and CNV after long-term intense cyclic light exposure, allowing the detailed study of the pathogenesis and treatment of age-related macular degeneration. CLINICAL RELEVANCE: The ability to study the progressive pathogenesis of age-related macular degeneration and CNV will provide detailed knowledge about the disease and aid in the development of target-specific therapy.
Lamivudine Inhibits<i>Alu</i>RNA-induced Retinal Pigment Epithelium Degeneration via Anti-inflammatory and Anti-senescence Activities
AbstractPurpose: Accumulation of the long noncoding Alu element RNA activates the NLRP3 inflammasome and leads to retinal pigment epithelium (RPE) cell death, a key event in the pathogenesis of geographic atrophy during late-stage age-related macular degeneration. Lamivudine (3TC) is a nucleoside analog reverse transcriptase inhibitor known to inhibit the NLRP3 inflammasome. Currently, the intracellular response of the senescence marker p16Ink4a to the long noncoding RNA is being actively studied. The present study aimed to assess the efficacy of 3TC against Alu RNA-induced RPE inflammation and senescence by evaluating changes in expression of the proinflammatory cytokines IL-18 and IL-1β and of p16INK4a in RPE cells. Methods: Cultured human RPE cells and in vivo mouse RPE cells were transfected with an in vitro-transcribed Alu RNA, and changes in IL-18, IL-1β, and p16Ink4a expression measured in the presences of 3TC or 3,4-(M)CA as a negative control. Results: Treatment with 3TC markedly reduced Alu RNA-induced expression of IL-18 and IL-1β in human and mouse RPE cells compared with the negative control. Further, Alu RNA-induced p16INK4a expression was suppressed by 3TC in human RPE cells. Conclusions: Our data suggest that Alu RNA accumulation contributes to RPE cell senescence in age-related macular degeneration and that this pathogenic process can be suppressed by 3TC. Translational Relevance: Further verifying this study leads to potential targets for age-related macular degeneration therapy.
Current Opinion in Ophthalmology · 2007 · 9 citations
Treatment of neovascular age-related macular degeneration: past, present and future directions
AbstractPURPOSE OF REVIEW: The treatment options of choroidal neovascularization due to age-related macular degeneration have expanded. Prior to ocular photodynamic therapy the only available treatment was laser photocoagulation. Clinicians and patients were not particularly enthusiastic despite its ability to stabilize vision. The purpose of the review is to review the past and current concepts of neovascular age-related macular degeneration therapy and to provide a short overview of upcoming treatments. RECENT FINDINGS: Photodynamic therapy provided us with the first realistic means to address subfoveal choroidal neovascularization lesions from age-related macular degeneration. Antivascular endothelial growth factors now allow better visual outcomes than mere stabilization of vision and other promising treatments are undergoing study at this time. SUMMARY: Age-related macular degeneration therapy has undergone a significant revolution in recent years. Understanding the historical perspective of treatment provides a better appreciation of current therapies. Still there is no cure for this disease and more promising treatments are currently under investigation.
IntechOpen eBooks · 2021 · 2 citations · open access
Recent Advances and New Perspectives in Managing Macular Degeneration
AbstractMacular degeneration is a blinding disease with huge socioeconomic costs. This book presents a comprehensive overview of macular degeneration, including age-related macular degeneration (AMD). Chapters address such topics as the disease state of macular degeneration, diagnosis and management of AMD, treatment considerations, and vision rehabilitation. It is a useful resource for both novice readers and experts in the field.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
